JPWO2020148548A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020148548A5 JPWO2020148548A5 JP2021541198A JP2021541198A JPWO2020148548A5 JP WO2020148548 A5 JPWO2020148548 A5 JP WO2020148548A5 JP 2021541198 A JP2021541198 A JP 2021541198A JP 2021541198 A JP2021541198 A JP 2021541198A JP WO2020148548 A5 JPWO2020148548 A5 JP WO2020148548A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aav vector
- use according
- monogenic
- nephrotic syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024167091A JP7835461B2 (ja) | 2019-01-18 | 2024-09-26 | ネフローゼ症候群を処置するためのａａｖ遺伝子療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1900702.0A GB201900702D0 (en) | 2019-01-18 | 2019-01-18 | Therapy |
| GB1900702.0 | 2019-01-18 | ||
| PCT/GB2020/050097 WO2020148548A1 (en) | 2019-01-18 | 2020-01-17 | Aav gene therapy for treating nephrotic syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024167091A Division JP7835461B2 (ja) | 2019-01-18 | 2024-09-26 | ネフローゼ症候群を処置するためのａａｖ遺伝子療法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022517407A JP2022517407A (ja) | 2022-03-08 |
| JPWO2020148548A5 true JPWO2020148548A5 (https=) | 2023-01-30 |
| JP2022517407A5 JP2022517407A5 (https=) | 2023-01-30 |
| JP7587506B2 JP7587506B2 (ja) | 2024-11-20 |
Family
ID=65528327
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021541198A Active JP7587506B2 (ja) | 2019-01-18 | 2020-01-17 | ネフローゼ症候群を処置するためのａａｖ遺伝子療法 |
| JP2024167091A Active JP7835461B2 (ja) | 2019-01-18 | 2024-09-26 | ネフローゼ症候群を処置するためのａａｖ遺伝子療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024167091A Active JP7835461B2 (ja) | 2019-01-18 | 2024-09-26 | ネフローゼ症候群を処置するためのａａｖ遺伝子療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12544460B2 (https=) |
| EP (2) | EP4516915A3 (https=) |
| JP (2) | JP7587506B2 (https=) |
| CN (2) | CN113543814B (https=) |
| AU (2) | AU2020208997B2 (https=) |
| CA (1) | CA3126429A1 (https=) |
| GB (1) | GB201900702D0 (https=) |
| WO (1) | WO2020148548A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201900702D0 (en) | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
| GB202003109D0 (en) | 2020-03-04 | 2020-04-15 | Univ Bristol | Gene therapy |
| GB202003618D0 (en) | 2020-03-12 | 2020-04-29 | Univ Bristol | Gene Therapy |
| GB202009039D0 (en) | 2020-06-15 | 2020-07-29 | Univ Bristol | Therapy |
| GB202103470D0 (en) * | 2021-03-12 | 2021-04-28 | Univ Bristol | Promoter |
| CN114592052A (zh) * | 2022-04-01 | 2022-06-07 | 中国人民解放军陆军军医大学第二附属医院 | 一种肾病综合征患者pdss2致病突变基因及其检测试剂 |
| EP4273243A1 (en) | 2022-05-02 | 2023-11-08 | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Nucleic acid constructs and vectors for podocyte specific expression |
| WO2025072667A2 (en) * | 2023-09-29 | 2025-04-03 | University Of Utah Research Foundation | Compositions and methods for treating phosphomannomutase 2 (pmm2) deficiency |
| CN117871216B (zh) * | 2024-03-12 | 2024-06-04 | 中日友好医院(中日友好临床医学研究所) | 一种石蜡标本中肾小球裂隙膜的三维可视化方法 |
| GB202414499D0 (en) * | 2024-10-02 | 2024-11-13 | Purespring Therapeutics Ltd | Methods |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| FR2804127B1 (fr) * | 2000-01-20 | 2004-12-24 | Inst Nat Sante Rech Med | Gene srn1 implique dans le syndrome nephrotique cortico- resistant, proteine codee par ce gene et utilisations diagnostiques et therapeutiques |
| WO2003082305A1 (en) | 2002-04-03 | 2003-10-09 | Naohide Yamashita | Drug containing human placenta-origin mesenchymal cells and process for producing vegf using the cells |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| WO2007125723A1 (ja) | 2006-04-28 | 2007-11-08 | Osaka University | 糸球体スリット蛋白誘導剤 |
| CN120174012A (zh) | 2013-10-24 | 2025-06-20 | 优尼科Ip有限公司 | 用于基因治疗神经疾病的aav-5假型载体 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| HK1249534A1 (zh) | 2015-04-06 | 2018-11-02 | 哈佛大学校长及研究员协会 | 用於非清髓性预处理的组合物和方法 |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| US20190022250A1 (en) | 2015-11-06 | 2019-01-24 | National University Corporation Kumamoto University | Pharmaceutical composition for preventing or treating heart failure |
| WO2017144080A1 (en) * | 2016-02-23 | 2017-08-31 | Eyeserv Gmbh | Gene therapy for the treatment of a disease of retinal cone cells |
| MX2019001920A (es) | 2016-08-19 | 2019-07-01 | Curevac Ag | Arn la terapia contra el cancer. |
| WO2018144709A2 (en) | 2017-02-01 | 2018-08-09 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating citrullenemia |
| GB201900702D0 (en) | 2019-01-18 | 2019-03-06 | Univ Bristol | Therapy |
| EP4273243A1 (en) | 2022-05-02 | 2023-11-08 | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca | Nucleic acid constructs and vectors for podocyte specific expression |
-
2019
- 2019-01-18 GB GBGB1900702.0A patent/GB201900702D0/en not_active Ceased
-
2020
- 2020-01-17 AU AU2020208997A patent/AU2020208997B2/en active Active
- 2020-01-17 EP EP24212299.2A patent/EP4516915A3/en active Pending
- 2020-01-17 WO PCT/GB2020/050097 patent/WO2020148548A1/en not_active Ceased
- 2020-01-17 CA CA3126429A patent/CA3126429A1/en active Pending
- 2020-01-17 US US17/422,739 patent/US12544460B2/en active Active
- 2020-01-17 JP JP2021541198A patent/JP7587506B2/ja active Active
- 2020-01-17 EP EP20701850.8A patent/EP3911368A1/en active Pending
- 2020-01-17 CN CN202080016138.4A patent/CN113543814B/zh active Active
- 2020-01-17 CN CN202510707055.4A patent/CN120683181A/zh active Pending
-
2024
- 2024-09-26 JP JP2024167091A patent/JP7835461B2/ja active Active
- 2024-11-15 US US18/949,585 patent/US20250064984A1/en active Pending
-
2026
- 2026-02-27 AU AU2026201536A patent/AU2026201536A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020148548A5 (https=) | ||
| JP2020514286A5 (https=) | ||
| JP2018537984A5 (https=) | ||
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| JP2019513794A5 (https=) | ||
| FI3906066T3 (fi) | Geeniterapiakonstrukteja wilsonin taudin hoitamiseksi | |
| JP2024054426A5 (https=) | ||
| CA2030988C (en) | Pharmaceutical for subcutaneous or intramuscular administration containing polypeptides | |
| JP2010155842A5 (https=) | ||
| JP2010500399A5 (https=) | ||
| JP2018527365A5 (https=) | ||
| JP2009545310A5 (https=) | ||
| JPWO2019156137A5 (https=) | ||
| Jülke et al. | Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery☆ | |
| JP2025090820A5 (https=) | ||
| JPWO2021181118A5 (https=) | ||
| CN116715752A (zh) | 凝血因子fviii蛋白变体、表达载体和用途 | |
| JP2020527167A5 (https=) | ||
| JPWO2020142653A5 (https=) | ||
| JPS61286325A (ja) | 後天的免疫不全症の治療剤 | |
| JP7490632B2 (ja) | Ｃｄ４ムテインおよびその使用方法 | |
| RU2536223C2 (ru) | Композиции и способы для лечения фиброза аорты | |
| US20210046025A1 (en) | Injection for Protecting Ischemic Myocardium and Preparation Method thereof | |
| JP2023020885A5 (https=) | ||
| BR112022022704A2 (pt) | Composições úteis para tratamento da doença de pompe |